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Abstract 
Background: Leptin has been linked to the pathology of several types of cancers related to obesity, 
particularly colon cancer. This could be related to leptin’ s influence on the equilibrium of specific 
intracellular mechanisms that control cellular growth, differentiation, apoptosis, neovascularization 
and invasiveness thus participating in the pathophysiology of colon cancer growth and metastasis. 
Additionally, ghrelin is a gut peptide secreted from the fundus of gastric mucosa and adiponectin is an 
adipocytokine released from adipose tissue and their low levels in obese subjects have been linked to 
an increased risk of development of colon cancer.  
Subjects  and  methods:  Forty  (40)  patients  were  enrolled  from  Cairo  University  hospitals  and 
included in this study beside the control group which comprised 20 age and sex-matched healthy 
subjects. Patients were divided into two groups: Group 1: Included 20 patients suffering from colon 
cancer (stage  II-A)  without  lymph  node involvement or distant  metastasis. Group 2: Included 20 
patients  suffering  from  colon  cancer  (stage  III-C)  with  lymph  node  involvement  but  no  distant 
metastasis.  Serum  Leptin,  ghrelin  and  adiponectin  were  measured  in  all  patients  using  a 
radioimmunoassy technique.  
Results: Serum leptin levels were significantly higher in colon cancer patients compared to that of 
control subjects (p<0.001). Serum leptin levels were also significantly higher in stage II-A patients as 
compared  to  stage  III-C  (p<0.001).  Serum  ghrelin  and  adiponectin  levels  were  found  to  be 
significantly lower in colon cancer patients compared to the control subjects (p<0.001).  Moreover, 
serum ghrelin and adiponectin levels were found to be significantly lower in patients belonging to 
stage III-C compared to stage II-A (p<0.001).  A negative correlation was noted between seum leptin 
levels and both serum ghrelin and adiponectin levels in colon cancer patients enrolled. Conclution: 
Serum leptin levels could serve as a good prognostic marker in colon cancer patients in addition to 
serum ghrelin and adiponectin levels to predict the severity and the development of colon cancer 
metastasis. 
Keywords  :  Serum  leptin,  serum  ghrelin,  serum  adiponectin,  colon  cancer,  lymph  node, 
matastasis. 
  
Introduction 
During  the  past  ten  years,  adipose 
tissue has been considered not only as a tissue 
responsible for calorie storage, but as one of 
the vital endocrine tissues in the body as well 
(1). Many cytokines called adipocytokines are 
produced  and  secreted  by  adipose  tissue.  
Leptin is the most available adipocytokine . It 
is a 16-kDa hormone that plays a key role in 
regulating  energy  intake  and  expenditure, 
including appetite and  hunger  thus  playing  a 
major  part  in  regulating  appetite  and  satiety 
and  modifying  food  consumption,  energy 
storage  and  body  mass  index 
(2).  Leptin  also 
makes  a  significant  contribution  to  lipid  and 
glucose  metabolism,  reproductive,  adrenal, 
and thyroid functions, cardiovascular system, 
immunity and brain functionality 
(3). 
Leptin  has  been  incriminated  in  the 
pathology of several types of cancers linked to 
obesity,  particularly  colon  cancer 
(4).  This 
could  be  related  to  leptin’s  influence  on  the 
equilibrium  of  specific  intracellular 
mechanisms  that  control  cellular  growth, 
differentiation,  apoptosis  and 
neovascularization,  thus  participating  in  the 
pathophysiology of cancer 
(5).  
Leptin promotes the production and secretion 
of several pro-inflammatory cytokines such as 
interleukin-6  (IL-6),  interleukin-1  β  (IL-1β) 
and  chemokine  (C-X-C  motif)  ligand  1 
(CXCL1) in humans, which have been linked 
to  colon  carcinogenesis 
(6).  Leptin  (mediated 
by  the  effect  of  CXCL1)  promotes  vascular 
endothelial growth factor (VEGF) activity by 
epithelial  cells,  and  thus  provides  a  tool  for 
tumor-associated  angiogenesis,  nurturing  Serum Leptin Hormone … 
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tumor  existence  and  proliferation 
(7). 
Therefore,  by  enhancing  angiogenesis,  leptin 
accelerates  tumor  growth  and  metastasis  of 
adjacent organs 
(8). 
Leptin  affects  many  cellular  signal 
transduction  pathways,  and  can  act  as  an 
important  gene  expression  modulator.  The 
genes  AKT1,  STAT3  and  MCL1  are  up-
regulated  at  the  early  stage  of  colon  cancer, 
and  on  the  other  hand  the  gene  STAT5B  is 
quelled 
(9).  
Additionally,  differences  in  the  gene 
expression  profile  between  early  and  late 
stages of colon cancer suggest that leptin plays 
a role in the dynamic and variable structure of 
the  malignant  tumor.    Leptin    may 
consequently be partly  accountable for tumor 
progression  by  means  of  transcription 
activation, repression or silencing 
(8).  
 Ghrelin  is  a  growth-hormone-
releasing  acylated  peptide.  It  is  a  28  amino 
acid  hormone  produced  by  P/D1 cells  lining 
the fundus of the human stomach.  It is known 
to have a variety  of  metabolic functions that 
range  from  stimulation  of  gastric  acid  and 
regulation  of  digestive  tract  motility  to 
regulation of energy storage and modulation of 
appetite 
(10).  In  some  respects,  it  can  be 
considered  as  the  opposite  of  the  hormone 
leptin; leptin is known to suppress the appetite. 
In  rats  and  mice,  systemic  or  central 
application  of  ghrelin  increases  food  intake 
and increases fat mass as a result of its action 
at the hypothalamus 
(11). In contrast to leptin, 
the satiety hormone, ghrelin plays a role at the 
beginning of a meal with ghrelin blood levels 
rising  before  and  falling  after  food 
consumption 
(10).  
The  physiological  role  of  ghrelin  is 
understood to be greater than simply its effect 
on metabolism; studies advocate that ghrelin is 
expressed  in  human  T  lymphocytes  and 
monocytes  and  acts  through  the  growth 
hormone  secretagogue  receptor  (type  1a)  to 
inhibit the expression of the pro-inflammatory 
cytokines  interleukin  1β,  interluekin  6,  and 
tumor  necrosis  factor-α 
(12)  thus  having  the 
opposite  effect  to  leptin  on  the  risk  of 
development of gastrointestinal tumors such as 
colon  cancer  and  subsequent  metastasis  to 
distant organs. 
Colon cancer has been proven to be an 
obesity-related disease, and adiponectin is one 
of  the  important  adipocytokines  that  is  also 
important  to  be  considered  in  colon  cancer 
patients. Adiponectin is secreted by adipocytes 
and consists of 244 amino acids that represent 
a full 30 kDa-long protein hormone. The gene 
for  Adiponectin  is  located  at  chromosomal 
band 3q27 
(13) . There is little  information  in 
literature  about  adiponectin  and  all  of  it  has 
been obtained  in the past ten  years. A study 
carried out in 2005 suggested that a decrease 
in  plasma  adiponectin  concentration  was 
associated  with  the  development  of  colon 
adenoma  in  Japanese  patients 
(14).  Later  in  a 
prospective case control study it was suggested 
that the risk of colorectal cancer is higher in 
patients  with  low  adiponectin  plasma  levels 
(15). A third study on a mouse model, showed 
that  adiponectin  depressed  colorectal 
carcinogenesis  and  leads  the  way  for  further 
investigations 
(16). 
Aim of the work 
The  aim  of  the  present  study  is  to 
determine if measuring serum leptin could be 
of  any prognostic value in patients with stage 
II-A colon cancer (a model of non-metastatic 
colon  cancer)  and  patients  with  stage  III-C 
colon  cancer  (a  model  of  colon  cancer 
spreading to adjacent lymph nodes just before 
the  occurrence  of  distant  metastasis).  The 
present  study  also  aims  at  investigating  the 
inter-relationship  between  serum  leptin  in 
colon  cancer  patients  enlisted    and  other 
adipocytokines  suspected    of  having  an 
influence  on  colon  cancer  development  and 
metastasis  such  as  serum  gherlin  and 
adiponectin. 
 
Subjects and Methods 
Subjects: 
Forty (40) colon cancer patients were enrolled 
from Cairo University Hospitals and included 
in  this  study  beside  the  control  group  which 
comprised  20  age  and  sex-matched  healthy 
subjects  not  complaining  from  any  disease 
related to the present study. Mean patient age 
was  55.6  ±  14  years.  The  patient  group 
comprised 20 males and 20 females.  Patients 
were divided into two groups: 
Group 1 :Included 20 patients suffering from 
colon cancer (stage II-A) without lymph node 
involvement  or  distant  metastasis  selected 
according to the TNM staging system from the 
American Joint Committee on Cancer (AJCC) 
(17).   
Group 2: Included 20 patients suffering from 
colon cancer (stage III-C) with metastasis to 4 
or  more  regional  lymph  nodes  but  with  no Tawfik M.S. 
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distant  metastasis  selected  according  to  the 
TNM staging system from the AJCC. 
Methods: 
All patients and controls were subjected to the 
following: 
Clinical  Evaluation:  full  history 
recording included age, sex, any  medications 
taken including the standard chemotherapeutic 
regimens followed in the patient groups. Pulse 
monitoring  and  blood  pressure  measurement 
were  carried  out  as  well  as  a  meticulous 
clinical examination for each subject. Weight 
and height were measured using the standard 
technique. BMI was calculated as body weight 
(kg)  divided  by  height  in  meters  squared 
(Kg/m 
2).  The  patients  enrolled  (20  colon 
cancer patients in each group) were all obese 
with a mean BMI of 33.5 ± 3.2. 
Staging  of  colon  cancer  was  done  using 
the TNM (for  tumours/nodes/metastases) 
system, from the AJCC. The TNM system (T= 
tumour,  N=  lymph  node,  M=  distant 
metastasis)  assigns  a  number  based  on  three 
categories. 
T categories for colorectal cancer: 
Tx: `No description of the tumour’s extent is 
possible because of incomplete information. 
Tis: The cancer is in the earliest stage (in situ). 
It involves only the mucosa. It has not grown 
beyond the  muscularis  mucosa (inner muscle 
layer). 
T1: The  cancer  has  grown  through  the 
muscularis  mucosa  and  extends  into  the 
submucosa. 
T2: The  cancer  has  grown  through  the 
submucosa  and  extends  into  the 
muscularispropria (thick outer muscle layer). 
T3: The  cancer  has  grown  through  the 
muscularis  propria  and  into  the  outermost 
layers of the colon or rectum but not through 
them. It has not reached any nearby organs or 
tissues. 
T4a: The cancer has grown through the serosa 
(also  known  as  the  visceral  peritoneum),  the 
outermost lining of the intestines. 
T4b: The cancer has grown through the wall 
of the colon  or rectum and  is attached to  or 
invades into nearby tissues or organs. 
 
N categories for colorectal cancer   
N categories indicate whether or not the cancer 
has spread to nearby lymph nodes and, if so, 
how many lymph nodes are involved. To get 
an  accurate  idea  about  lymph  node 
involvement, most doctors recommend that at 
least  12  lymph  nodes  be  removed  during 
surgery and looked at under a microscope. 
Nx: No  description  of  lymph  node 
involvement  is  possible  due  to  incomplete 
information. 
N0: No cancer in nearby lymph nodes. 
N1: Cancer cells are found in or near 1 to 3 
nearby lymph nodes. 
  N1a: Cancer cells are found in 1 nearby 
lymph node. 
  N1b: Cancer  cells  are  found  in  2  to  3 
nearby lymph nodes. 
  N1c: Small  deposits  of  cancer  cells  are 
found in areas of fat near lymph nodes, 
but not in the lymph nodes themselves. 
N2: Cancer  cells  are  found  in  4  or  more 
nearby lymph nodes. 
  N2a: Cancer  cells  are  found  in  4  to  6 
nearby lymph nodes. 
  N2b: Cancer cells are found in 7 or more 
nearby lymph nodes. 
M categories for colorectal cancer 
M categories  indicate  whether  or  not  the 
cancer  has  spread  (metastasized)  to  distant 
organs,  such  as  the  liver,  lungs,  or  distant 
lymph nodes. 
M0: No distant spread is seen. 
M1a: The cancer has spread to 1 distant organ 
or set of distant lymph nodes. 
M1b: The  cancer  has  spread  to  more  than  1 
distant organ or set of distant lymph nodes, or 
it has spread to distant parts of the peritoneum 
(the lining of the abdominal cavity). 
 
Stage grouping 
Once a person's T, N, and M categories have 
been  determined,  usually  after  surgery,  this 
information  is  combined  in  a  process 
called stage grouping. The stage is expressed 
in  Roman  numerals  from  stage  I  (the  least 
advanced)  to  stage  IV  (the  most  advanced). 
Some stages are subdivided with letters. 
Stage 0 
Tis,  N0,  M0: The  cancer  is  in  the  earliest 
stage. It has not grown beyond the inner layer 
(mucosa) of the colon or rectum. This stage is 
also  known  as carcinoma  in 
situ or intramucosal carcinoma. 
Stage I 
T1-T2,  N0,  M0:  The  cancer  has  grown 
through  the  muscularis  mucosa  into  the 
submucosa  (T1)  or  it  may  also  have  grown 
into  the  muscularis  propria  (T2).  It  has  not 
spread to nearby lymph nodes or distant sites.  Serum Leptin Hormone … 
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Stage II-A 
T3,  N0,  M0: The  cancer  has  grown  into  the 
outermost layers of the colon or rectum but has 
not gone through them (T3). It has not reached 
nearby  organs.  It  has  not  yet  spread  to  the 
nearby lymph nodes or distant sites. 
Stage II-B 
T4a, N0, M0: The cancer has grown through 
the  wall  of  the  colon  or  rectum  but  has  not 
grown  into  other  nearby  tissues  or  organs 
(T4a).  It  has  not  yet  spread  to  the  nearby 
lymph nodes or distant sites. 
Stage II-C 
T4b, N0, M0: The cancer has grown through 
the wall of the colon or rectum and is attached 
to  or  has  grown  into  other  nearby  tissues  or 
organs  (T4b).  It  has  not  yet  spread  to  the 
nearby lymph nodes or distant sites. 
Stage III-A 
One of the following applies. 
T1-T2,  N1,  M0: The  cancer  has  grown 
through the mucosa into the submucosa (T1) 
and it may also have grown into the muscularis 
propria  (T2).  It  has  spread  to  1  to  3  nearby 
lymph  nodes  (N1a/N1b)  or  into  areas  of  fat 
near  the  lymph  nodes  but  not  the  nodes 
themselves (N1c). It has not spread to distant 
sites. 
T1, N2a, M0: The cancer has grown through 
the  mucosa  into  the  submucosa  (T1).  It  has 
spread to 4 to 6 nearby lymph nodes (N2a). It 
has not spread to distant sites. 
Stage III-B 
One of the following applies: 
T3-T4a, N1, M0: The cancer has grown into 
the  outermost  layers  of  the  colon  or  rectum 
(T3) or through the visceral peritoneum (T4a) 
but  has  not  reached  nearby  organs.  It  has 
spread  to  1  to  3  nearby  lymph  nodes 
(N1a/N1b) or into areas of fat near the lymph 
nodes but not the nodes themselves (N1c). It 
has not spread to distant sites. 
T2-T3, N2a, M0: The cancer has grown into 
the  muscularis  propria  (T2)  or  into  the 
outermost layers of the colon or rectum (T3). 
It  has  spread  to  4  to  6  nearby  lymph  nodes 
(N2a). It has not spread to distant sites. 
T1-T2,  N2b,  M0: The  cancer  has  grown 
through the mucosa into the submucosa (T1) 
or it may also have grown into the muscularis 
propria (T2). It has spread to 7 or more nearby 
lymph nodes (N2b). It has not spread to distant 
sites. 
Stage III-C 
One of the following applies: 
T4a, N2a, M0: The cancer has grown through 
the wall of the colon or rectum (including the 
visceral  peritoneum)  but  has  not  reached 
nearby  organs (T4a). It has spread to 4 to 6 
nearby lymph nodes (N2a). It has not spread to 
distant sites. 
T3-T4a, N2b, M0: The cancer has grown into 
the  outermost  layers  of  the  colon  or  rectum 
(T3) or through the visceral peritoneum (T4a) 
but  has  not  reached  nearby  organs.  It  has 
spread  to  7  or  more  nearby  lymph  nodes 
(N2b). It has not spread to distant sites. 
T4b,  N1-N2,  M0: The  cancer  has  grown 
through the wall of the colon or rectum and is 
attached  to  or  has  grown  into  other  nearby 
tissues or organs (T4b). It has spread to at least 
one  nearby  lymph  node  or  into  areas  of  fat 
near the lymph nodes (N1 or N2). It has not 
spread to distant sites. 
Stage IV-A 
Any T, Any N, M1a: The cancer may or may 
not have grown through the wall of the colon 
or rectum, and it may or may not have spread 
to  nearby  lymph  nodes.  It  has  spread  to  1 
distant organ (such as the liver or lung) or set 
of lymph nodes (M1a). 
Stage IV-B 
Any T, Any N, M1b: The cancer may or may 
not have grown through the wall of the colon 
or rectum, and it may or may not have spread 
to nearby lymph nodes. It has spread to more 
than 1 distant organ (such as the liver or lung) 
or  set  of  lymph  nodes,  or  it  has  spread  to 
distant parts of the peritoneum (the lining of 
the abdominal cavity) (M1b). 
     All  patients  involved  in  the  study  were 
staged after a resection-anastomosis surgery of 
the colon including a safety margin and biopsy 
followed  by  histopathology  of  the  resected 
portion of the colon affected by the tumour as 
well  as  lymph  nodes  removed  during  the 
operation.  
Laboratory  assessment:  Venous  blood 
sampling  was  performed  after  a  12h  fasting 
then patients were subjected to the following: 
1.  Routine  complete  blood  picture:  was 
carried  out  using  an  electronic  Coulter 
counter  (Cobas,  Roch  Inc.  Switzerland) 
according  to  the  standards  specified  by 
Cheng et al 
(18). 
2.  Routine  complete  liver  and  kidney 
function  tests  were  also  undertaken  for 
each participant in this work.  
3. Serum Leptin  assessment:   The level  of 
serum  leptin  was  analysed  in  all  subjects Tawfik M.S. 
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enrolled by radio- immune assessment using 
recombinant  human  leptin  (Leptin-  Human 
Ria-CT) according to the method described 
by Feldkamp and Smith 
(19). 
4-    Serum Gherlin assessment: 
The level of serum gherlin was evaluated in all 
subjects  joining  in the study by using serum 
immune-reactive ghrelin that was measured in 
duplicates  by  a  radioimmunoassay  involving 
125 I-labelled Ghrelin and a Ghrelin antiserum 
to  determine  the  level  of  active  Ghrelin  in 
serum by the double antibody/PEG technique. 
This  was  done  according  to  the  method 
described  by  Feldkamp  and  Smith
  (19).The 
lower  and  upper  limits  of  detection  were  24 
and 740 pmol per liter.  
5-Serum adiponectin assessment: 
The level of serum adiponectin was estimated 
in  all  subjects  joining  in  the  study  by  using 
serum  immune-reactive  adiponectin  that  was 
measured  in  duplicates  by  a 
radioimmunoassay  that  utilizes  125I-labeled 
murine  adiponectin  and  a  multispecies 
adiponectin rabbit antiserum to determine the 
level  of  adiponectin  in  serum  by  the  double 
antibody/PEG  technique.  The  adiponectin 
standards  were  prepared  using  recombinant 
human adiponectin and were used to determine 
the circulating levels of adiponectin in human 
serum samples. This was done according to the 
method described by Feldkamp and Smith
(19). 
Statistical analysis  
         Statistical analysis was performed using 
Statistica  v.  10  software.  Quantitative  results 
were  expressed as  mean ± SD. T-test  or the 
Mann-Whitney  U  test  was  used  to  compare 
quantitative  variables  in  the  two  qualitative 
groups and ANOVA or the Kruskal Wallis test 
was  used  in  more  than  two  groups.  Pearson 
test  and  Spearman's  rho  test  were  used  to 
assess  the  correlation  of  two  quantitative 
variables.  P  value  <0.05  was  considered  as 
statistically  significant.  P  value  <0.01  was 
considered  as  statistically  highly  significant. 
All  statistical  analysis  were  performed 
according to Snedcor and Cochran 
(20). 
Results 
A very highly significant difference (p<0.01) 
in  serum  leptin  levels  was  found  between 
colon cancer patients enlisted in this study and 
healthy  control  subjects.  Also  a  highly 
significant  difference  (p<0.01)  was  found 
between  colon  cancer  patients  without 
metastasis  (stage  II-A)  and  those  with 
metastasis  (stage  III-C).  These  results  are 
illustrated in table 1 as well as figure 1. 
 
 
Table (1): Mean ±SD and P values of serum leptin, gherlin and adiponectin levels in control 
subjects, colon cancer patients without lymph node metastasis (stage II-A) and colon cancer 
patients with lymph node metastasis (stage III-C) 
 
  Controls 
(n=20) 
Colon Cancer 
without 
metastasis (n=20) 
Colon Cancer 
with metastasis 
(n=20) 
Mean Serum Leptin 
Level (ng/ml) ± SD 
 
8.6±0.8 
   
  25.2 ± 2.8  30.1 ± 4.3 
P value  <0.001** 
Mean Serum Gherlin 
Level (pmol/l) ± SD 
 
324.1± 14.2 
 
229.05± 12.4 
 
156± 11.5 
 
P value  <0.001** 
Mean Serum 
Adiponectin Level 
(pmol/l) ± SD 
 
8.1± 
0.9 
 
   
 
6.2± 0.7 
 
2.5± 0.4 
 
P value  <0.001** 
SD: standard deviation, P: probability, p< 0.05 = 
*Significant, p<0.01 =** highly significant. 
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Figure 1: Mean ±SD serum leptin levels (ng/ml) in controls, colon cancer patients without lymph 
node metastasis (stage II-A) and those with lymph node metastasis (stage III-C). 
 
In addition, a very highly significant difference (p<0.01) in serum gherlin levels was observed 
between colon cancer patients enrolled in this study and healthy control subjects. A highly significant 
difference (p<0.01) was also found between colon cancer patients without metastasis (stage II-A) and 
those with metastasis (stage III-C). These results are illustrated in table 1 as well as figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 : Mean ±SD serum gherlin levels (pmol/l) in controls, colon cancer patients without 
lymph node metastasis (stage II-A) and those with metastasis (stage III-C) respectively. 
 
A negative correlation was observed between seum leptin and serum gherlin levels in the two 
groups of colon cancer patients enrolled in the study. (r = - 0.50, r
2 = 0.25). This correlation is shown 
in figure 3. 
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Figure 3: Correlation between serum leptin (ng/ml) and ghrelin levels (pmol/l) in colon cancer 
patients.  
A very highly significant difference (p<0.01) in serum adiponectin levels was found between 
colon cancer patients enrolled in this study and control subjects. Also a highly significant difference 
(p<0.01) was found between colon cancer patients without metastasis (stage II-A) and those with 
metastasis (stage III-C). These results are illustrated in table 1 as well as figure 4.  
 
 
 
Figure 4 : Mean ± SD serum adiponectin levels (µg/ml) in controls, colon cancer patients 
without lymph node metastasis (stage II-A) and those with lymph node metastasis (stage III-C). 
 
A negative correlation was observed between serum  leptin and serum adiponectin levels in 
the two groups of colon cancer patients enrolled in the study. (r = - 0.51, r
2 = 0.26). This correlation is 
shown in figure 5. 
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Figure 5: Correlation between serum leptin (ng/ml) and adiponectin levels (µg/ml) in colon 
cancer patients.  
 
Discussion 
Colorectal  cancer  is  considered  the 
second leading cause of cancer-related deaths 
in  many  countries  worldwide  including  the 
United  States.  Early  diagnosis, 
nevertheless, could  in  many  cases  lead  to  a 
better prognosis. Almost all colon cancers start 
in glands in the lining of the colon and rectum. 
However; colon cancer is usually diagnosed at 
advanced stages, when it is usually fatal 
(21). 
Excess body weight, as defined by the 
body  mass  index  (BMI),  has  been  linked  to 
several diseases and includes subjects who are 
overweight  (BMI≥25-29.9  kg/m
2)  or  obese 
(BMI≥30  kg/m
2).  Around  11%  of  colorectal 
cancer  (CRC)  cases  have  been  attributed  to 
overweight  and  obesity  in  Europe. 
Epidemiological  data  suggest  that  obesity  is 
associated  with  a  30-70%  increased  risk  of 
colon cancer in men, whereas the association 
is less consistent in women. The relative risk 
of colorectal cancer of obese patients is about 
1.5  times  higher  than  in  normal-weight 
individuals and obesity is also associated with 
premalignant colorectal adenoma. Visceral fat, 
or abdominal obesity, seems to be of greater 
concern  than  subcutaneous  fat  obesity,  and 
any1 kg/m
2 increase in BMI confers additional 
risk. Obesity might be associated with worse 
cancer  outcomes,  such  as  recurrence  of  the 
primary  cancer  or  mortality.  Several  factors, 
including  reduced  sensitivity  to  anti-
angiogenic-therapeutic  regimens,  might 
explain these  differences 
(22). Comstock et al 
(23) documented that obesity is a key risk factor 
for the development of colon cancer in white 
obese males. 
 
In  the  present  study,  the  patients 
belonging to the two groups selected (20 colon 
cancer  patients  each)  were  all  obese  with  a 
mean BMI of 33.5 ± 3.2.  
Aleksandrova  et  al 
(24)  estimated  the 
extent to which biomarkers with inflammatory 
and metabolic actions mediate the association 
of  adiposity  measures,  waist  circumference 
(WC) and body mass index (BMI), with colon 
cancer in men and women.  
It  is  hypothesized  that  obesity  is  a 
chronic  low  grade  inflammatory  process  that 
results in increased secretion of products from 
adipose tissue that include leptin, interleukin-
6, interleukin-17, tumor necrosis factor-alpha, 
and  associated  decreased  blood  levels  of 
ghrelin and adiponectin that appear to have a 
shielding  effect  against  the  development  of 
several  types  of  cancer,  including  colon 
cancer.  These  products  induce  malignancy-
related  metabolic  alterations  in  colon  cancer 
cells  leading  to  metabolic  syndrome,  insulin 
resistance  and  modifications  in  levels  of    
adipocytokines  that  seem  to  be  of  great 
importance 
(25).  
The  leptin  hormone  can  modulate 
several  important  functions  of  the 
gastrointestinal  tract. It interacts  with  the 
vagus  nerve  and  cholecystokinin  to  delay 
gastric emptying and has a complex effect on 
motility of the small bowel. Leptin modulates 
absorption  of  macronutrients  in  the 
gastrointestinal  tract  differentially  in 
physiologic  and  pathologic  states.  In 
physiologic  states,  exogenous leptin has  been 
shown  to  decrease  carbohydrate  absorption Tawfik M.S. 
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and  to  increase  the  absorption  of  small 
peptides  by  the  PepT1  di-/tripeptide 
transporter.  In  certain  pathologic 
states, leptin has  been  shown  to  increase 
absorption  of  carbohydrates,  proteins,  and 
fat. The  hormone has  been  shown  to  be 
upregulated  in  the colonic mucosa  in  patients 
with  inflammatory  bowel  disease. Leptin 
stimulates  gut  mucosal  cell  proliferation  and 
inhibits apoptosis. These functions have led to 
speculation  about  the  role  of leptin in 
tumorigenesis  in  the  gastrointestinal  tract, 
which  is  complicated  by  the  multiple 
immunoregulatory effects of this hormone
 (26).  
Kemik et al 
(27) investigated the inter-
relationship  between  leptin,  associated 
cytokines and the development of colon cancer 
to  elaborate these suspected links. The study 
found  significantly  higher  serum  C-  reactive 
protein (CRP), interleukin 1α (IL-1α), IL-1β, 
IL-6,  IL-8,  IL-10,  tumour  necrosis  factor  α 
(TNF-α), midkine, vascular endothelial growth 
factor-A (VEGF-A), VEGF-C, VEGF receptor 
1  (VEGFR1)  and  leptin  in  colon  cancer 
patients. These factors are known to promote 
chronic inflammatory processes and enhanced 
cell  growth  and  proliferation  together  with 
increased  angiogenesis  culminating  into 
enhanced carcinogenesis. 
 Miyoshi  et  al 
(28)  also  hypothesized 
that  leptin  plays  a  pivotal  role  in  the 
pathogenesis of colorectal cancer (CRC).   
The  present  study  showed  a  very 
highly significant statistical increase in serum 
leptin levels in colon cancer patients compared 
to normal healthy controls (p< 0.001). These 
results were very similar to those of Guadagni 
et al 
(29) and Chia et al 
(30) who noted that leptin 
levels  were  significantly  higher  in  colon 
cancer  patients  compared  to  healthy  control 
subjects. Yet, these results were contradictory 
to  those  of  Arpaci  et  al 
(31)  who  found 
significantly  lower  serum  levels  of  leptin  in 
patients with colorectal cancer. They explained 
this  discrepancy  with  other  studies  by 
suggesting that the increased weight of colon 
cancer  patients  in  the  earlier  stages  of  the 
disease was not the sole factor in determining 
their serum leptin levels and that other factors 
could be involved. Similarly, Kosovva et al 
(32) 
also  speculated  that  leptin  levels  in  colon 
cancer  patients  were  not  statistically 
significantly different from those in the benign 
group.   
 Elevated  serum  leptin  levels  have 
been incriminated in colon cancer growth and 
development of metastasis to lymph nodes or 
distant  metastasis 
(33).  Tutino  et  al 
(34) 
documented  that  high  circulating  levels 
of leptin receptor  occur  in  patients  with 
advanced stage  of colon cancer, suggesting a 
role  of  leptin in cancer progression  and 
aggressiveness. The results of a study done by 
Erkasap et al 
(35) suggested a role of leptin on 
the  progression  of  colon  carcinoma  to 
metastatic disease without weight loss.  
The present study included two groups 
of patients. Group 1 included 20 patients who 
were  diagnosed  as  stage  II-A  colon  cancer 
(without  lymph  node  involvement  or  distant 
metastasis) while group 2 included 20 patients 
with stage III-C colon cancer with 4 or more 
lymph nodes involved. The selection of these 
patients  was  based  on  the  study’s  aim  to 
compare  colon  cancer  patients  who  did  not 
have lymph node involvement and those who 
did as regards serum leptin levels in order to 
predict  the  increased  risk  of  lymph  node 
metastasis  and  eventual  distant  metastasis 
using  this  hormone  as  a  prognostic  marker. 
The  results  showed  that  serum  leptin  levels 
were significantly higher in patients with stage 
III-C  colon  cancer  compared  to  stage  II-A 
colon cancer patients (p<0.001). These results 
are in agreement with those of Wang et al 
(36) 
who  found  significantly  higher  serum  leptin 
levels  in  stage  III  colon  cancer  patients 
compared to those belonging to stage II.   
Ghrelin is  a  metabolism-regulating 
hormone  recently  investigated  for  its  role 
in cancer survival and progression. Moreover, 
low  ghrelin levels  observed  in  obese  people 
may be implicated in cancer development and 
progression.  Limited  data  are  currently 
available  on the  effects exerted by ghrelin on 
intracellular  proteolytic  pathways  in cancer. 
Both  the  lysosomal  and  the  proteasomal 
systems  are  fundamental  in  cellular 
proliferation  and  apoptosis  regulation. 
Preliminary  in  vitro  fluorimetric  assays  have 
evidenced for the first time a direct inhibition 
of  20S  proteasomes  by  ghrelin,  particularly 
evident for the trypsin-like activity 
(37).  
Many  studies  have  pointed  out  a 
possible role of gut peptides, such as   ghrelin, 
in  the  pathogenesis  of  gastrointestinal 
malignancies including colon cancer which is 
one of the most common death causes in the 
western world 
(38).   Serum Leptin Hormone … 
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The  present  study  showed  that  there 
was  a  statistically  significant  difference  in 
serum  ghrelin  levels  of  the  patients  vs.  the 
controls, with the patients having much lower 
levels (p<0.001). These results are  confirmed 
Legakis et al.
(39) who found that colon cancer 
patients  had  significantly  lower  circulating 
levels of ghrelin than healthy controls. 
The role of low serum levels of ghrelin 
in  enhancing  cell  proliferation  and  apoptosis 
has  been  illustrated,  however;  studies  also 
implicate  that  low  levels  of  ghrelin  may 
influence the cancer cells motility or ability to 
metastasize.    D'Onghia  et  al 
(38)  found  that 
ghrelin plays a role in protecting against colon 
cancer metastasis.  
 
The  results    of  the  present  study 
showed  that  serum  ghrelin  levels  were 
significantly lower in patients with stage III-C 
colon  cancer  compared  to  stage  II-A  colon 
cancer patients (p<0.001) showing a possible 
protective role for ghrelin against colon cancer 
lymph node affection and metastasis.  
 
A  negative  correlation  was  observed 
between serum leptin levels and serum gherlin 
levels in the patients enrolled in this study. A 
similar  study  done  by  Kemik  et  al 
(40)  also 
established  a  negative  correlation  between 
serum  leptin  and  ghrelin  in  colon  cancer 
patients.  On  the  other  hand,  such  a  negative 
correlation  could  not  be  observed  in  another 
study  carried  out  by  Wolf  et  al.
(41)  who 
investigated serum leptin and ghrelin levels in 
colon  cancer  patients.  This  discrepancy  may 
be  attributed  to  the  fact  that  the  patients 
enrolled in the latter study were belonging to a 
more advanced stage of colon cancer and were 
suffering  from  cachexia  with  disturbed 
leptin/ghrelin balance. 
Another adipocytokine investigated in 
this study was adiponectin. This hormone has 
some known effects on the metabolic process 
such as gluconeogenesis, glucose uptake, lipid 
β-oxidation,  triglyceride  clearance,  protection 
from  endothelial  dysfunction,  insulin 
sensitivity and weight loss 
(42). 
Recent  studies  have  indicated  a 
significant  correlation  between  the  reduced 
plasma  adiponectin  levels  (associated  with 
obesity)  and  the  increased  risk  of  various 
cancers. Additionally, these studies have also 
demonstrated some of the antiangiogenic and 
antitumoral  effects  of  adiponectin 
(43). 
Endometrial, breast, prostate, colon, pancreatic 
cancer, and more recently non-small cell lung 
cancer and esophageal cancer have been found 
to  be  correlated  with  low  serum  adiponectin 
levels. 
Adiponectin  exerts  its  effects  via  5′ 
adenosine  monophosphate-activated  protein 
kinase  (AMPK).  Increased  concentrations  of 
adenosine  monophosphate  (AMP),  calcium-
dependent kinases and Ser/Thr liver kinase B1 
(LKB1) contribute to AMPK activation which 
in  turn  interferes  with  cellular  growth 
signaling  through  mammalian  target  of 
rapamycin  (mTOR)  thus  inhibiting  the 
promotion  of  carcinogenesis.  AMPK  also 
promotes  growth  arrest  and  apoptosis  via 
increased p53 and p21 expression, respectively 
(44). In contrast, the findings of a study done by 
Song et al (2013) 
(45) supported a positive role 
for adiponectin in colorectal carcinogenesis in 
men.  They  documented  an  association  of 
plasma adiponectin and soluble leptin receptor 
(sOB-R) with colorectal cancer . 
The  present  study  showed  that  there 
was a highly significant statistical difference in 
serum adiponectin levels  of the  colon cancer 
patients  vs.  the  controls  with  the  patients 
having  much  lower  levels  (p<0.001). These 
results are in accordance with other studies by 
Gulcelik et al 
(46) and Guadagni et al 
(9) that 
demonstrated  significantly  lower  levels  of 
adiponectin in colon cancer patients compared 
to control subjects. 
In  addition,  adiponectin  via  AMPK 
pathway  causes  inhibition  of  tumor  cell 
adhesion  and  migration  in  general  thus 
inhibiting  the  metastasis  of  many  types  of 
tumours 
(47). The results  of the present study 
showed  that  serum  adiponectin  levels  were 
significantly lower in patients with stage III-C 
colon  cancer  compared  to  stage  II-A  colon 
cancer patients (p<0.001) showing a possible 
sheilding  role  for  adiponectin  against  colon 
cancer  lymph  node  affection  or  metastasis. 
These  results  are  in  agreement  with  another 
study by Gialamas et al 
(48) that demonstrated 
that  serum  adiponectin  levels  and  tissue 
expression  of  adiponectin  receptors  are 
associated  with  risk,  stage,  and  grade  of 
colorectal cancer.   
Data of the present work speculated a 
negative  correlation  between  serum  leptin 
levels  and  serum  adiponectin  levels  in  the 
patients joining in this study. This result is in 
accordance with that of Gauadagni et al 
(7) who Tawfik M.S. 
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demonstrated  that  leptin  inversely  correlated 
with adiponectin in colon cancer patients. 
The  results  of  the  present  study 
highlighted important alterations occurring in 
serum adipocytokines, (leptin and adiponectin) 
in addition to the gut peptide ghrelin in colon 
cancer patients. It could be concluded from the 
striking features of this study that serum leptin 
levels could serve as a good prognostic marker 
to predict the clinical outcome of colon cancer 
and  subsequent  occurrence  of  metastasis  in 
patients  especially  as  it  is  the  most  readily 
available  adipocytokine  secreted  by 
adipocytes.  In  addition  to  this,  measuring 
serum levels of this hormone could also help 
clinicians  decide  whether  or  not  to  start 
aggressive  therapy  at  an  earlier  stage  before 
the occurrence of lymph node involvement or 
metastasis  depending  on  the  predictive  value 
of  leptin  hormone.  Serum  ghrelin  and 
adiponectin hormones are the counterparts of 
leptin and their determination in serum could 
also be used in conjunction with serum leptin 
level determination to predict clinical outcome 
and  prognosis  in  these  patients.  However; 
further investigations are required to add more 
information on the relationship between serum 
leptin levels and colon cancer staging. 
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